Segment Reporting (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Segment Reporting
Number of operating segments | segment	1
Revenue	$ 63,723	$ 58,443	$ 51,494
Cost of product revenue	5,626	5,281	4,540
Research and Development
Stock-based compensation	(33,109)	(17,825)	(16,964)
Depreciation	(3,786)	(2,983)	(2,109)
Interest expense	(13,577)	(11,338)	(7,022)
Interest income	20,282	3,983	798
Net Income (Loss)	(193,506)	(80,736)	(71,038)
Single Reportable Segment
Segment Reporting
Revenue	63,723	58,443	51,494
Cost of product revenue	5,626	5,281	4,540
Research and Development
Direct Program Expenses: AXPAXLI for wet AMD	57,507	8,750	5,296
Direct Program Expenses: Other clinical and preclinical programs	8,099	11,191	7,892
Unallocated expenses, Personnel costs	28,625	22,617	20,854
Unallocated expenses, All other costs	16,236	5,720	8,510
Selling & Marketing	38,029	36,564	34,920
General and Administrative	38,861	23,838	23,766
Facilities	5,626	6,056	5,297
Stock-based compensation	33,109	17,825	16,964
Depreciation	3,786	2,983	2,109
Interest expense	20,282	3,983	798
Interest income	(13,577)	(11,338)	(7,022)
Other non-operating items	(28,430)	9,001	13,840
Net Income (Loss)	$ (193,506)	$ (80,736)	$ (71,038)